FIELD: medicine; molecular-genetic diagnostics.
SUBSTANCE: biological material is sampled, and genomic DNA is isolated with subsequent genotyping of gene HLA-C alleles. In case of determination of the presence of HLA-C*12:03 allele, a high risk of the necessity of the use of oxygen therapy in COVID-19 is predicted.
EFFECT: invention provides for an increase in the accuracy of predictive assessments of the risk of the necessity of the use of oxygen therapy in COVID-19 for persons of the Russian population aged from 35 to 60 years.
3 cl, 1 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR ASSESSING THE RISK OF DEVELOPMENT OF SEVERE COVID-19 | 2021 |
|
RU2751410C1 |
| METHOD FOR ASSESSING RISK OF SEVERE FORM OF COVID-19 | 2021 |
|
RU2747097C1 |
| METHOD FOR PREDICTING THE RISK OF DEVELOPING COVID-19 IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES | 2022 |
|
RU2783422C1 |
| METHOD FOR ASSESSING THE RISK OF DEVELOPING A SEVERE COURSE OF CoVID-19 | 2022 |
|
RU2782796C1 |
| METHOD FOR PREDICTION OF RISK OF FATAL OUTCOME IN PATIENTS WITH SEVERE AND MODERATE COURSE OF COVID-19 DURING PREVENTIVE ANTI-INFLAMMATORY THERAPY | 2021 |
|
RU2770357C1 |
| METHOD FOR PREDICTING THE RISK OF SEVERE COVID-19 IN A PATIENT | 2022 |
|
RU2791487C1 |
| METHOD FOR ASSESSING THE RISK OF DEVELOPING A SEVERE COURSE OF CORONAVIRUS INFECTION IN WOMEN | 2021 |
|
RU2761138C1 |
| METHOD OF PREDICTING THE RISK OF DEATH FROM COVID-19 IN YOUNG PATIENTS | 2023 |
|
RU2803002C1 |
| ARTIFICIAL GENE ENCODING THE BSI-COV-UB IMMUNOGEN PROTEIN, RECOMBINANT PLASMID DNA PBSI-COV-UB, WHICH ENSURES THE EXPRESSION OF THE TARGET GENE, AND AN ARTIFICIAL POLYEPITOPE BSI-COV-UB IMMUNOGEN PROTEIN CONTAINING UBIQUITIN AND EPITOPES OF SARS-CoV-2 VIRUS ANTIGENS AND INDUCING SARS-CoV-2-SPECIFIC T-CELL IMMUNITY | 2023 |
|
RU2806590C1 |
| METHOD FOR PREDICTION OF OUTCOME OF ACUTE DISEASE CAUSED BY NEW CORONAVIRUS INFECTION COVID-19 | 2021 |
|
RU2766347C1 |
